CN106029102A - Tissue Repair and Rejuvenation Using Platelet Rich Plasma - Google Patents

Abstract

The present application relates to cosmetic methods for improving skin conditions. The methods generally include administering platelet rich plasma and cultured autologous cells to a subject after performing a microneedle procedure. The platelet rich plasma and autologous cells can be applied topically to the skin surface or injected into the dermis or subcutaneous tissue. The method can be used to improve conditions such as acne scars, traumatic scars, hyperpigmentation, fine lines, wrinkles, stretch lines, and hair loss.

Description

Tissue Repair and Rejuvenation Using Platelet Rich Plasma

field of invention

The present application relates to methods for administering a platelet-rich plasma (PRP) composition to a subject. Specifically, the method may involve topically applying the PRP composition to the skin surface after microneedling, or injecting the PRP composition into subcutaneous or skin tissue. The PRP composition will typically include cultured autologous cells, such as cultured autologous fibroblasts. Conditions such as acne scars, traumatic scars, hyperpigmentation, fine lines, wrinkles, stretch marks, and hair loss can be treated using the composition.

Background of the invention

The injection of synthetic materials into the body, and especially into the face, to achieve cosmetic results began at the end of the nineteenth century. For example, paraffin injections to correct facial contour defects were accepted for a brief period in the years leading up to World War I. However, complications and poor long-term outcomes led to the practice being abandoned. Injectable silicone became available in the early 1960s, but complications such as local and systemic reactions to silicone, migration of injectables, and local tissue damage limited its use.

Poor results obtained with injection of non-biological materials have prompted attempts to use exogenous proteins such as bovine atelocollagen as injectable filler materials to correct skin defects and/or cosmetically improve the appearance of the skin. However, the use of atelocollagen has not proven to be very satisfactory since resorption of this material occurs without displacement by host material and patients often develop immune reactions and drug resistance to repeated injections of atelocollagen. Due to the limitations of bovine atelocollagen, human collagen products and other autologous cell compositions derived from placenta or autologous tissue have been developed, but their use as injectables has also provided unsatisfactory results.

Over the past 15 to 20 years, a procedure applied to damaged or aging skin to improve its appearance is micro-needling. The microneedle device creates tiny wounds in the skin, which stimulate collagen production through the body's natural healing process. However, the amount of collagen produced by microneedling is generally not as great as that seen with other skin resurfacing techniques. Clinicians have also attempted to apply various types of cells to the skin after microneedling. However, the results were poor because the cells could not be successfully absorbed.

Accordingly, alternative methods for therapeutically or cosmetically improving the condition of the skin are desired.

Summary of the invention

Described herein is a method for cosmetically improving the condition of skin comprising applying to the skin a platelet-rich plasma composition, an autologous cell composition, or a combination thereof following a microneedling procedure. Microneedling creates pores in the skin surface that improve absorption of the platelet rich plasma or autologous cell composition beneath the skin surface, thereby providing enhanced tissue regeneration. Given that the platelet rich plasma is prepared from the subject's own blood, there is no risk of the subject developing an immune reaction to the composition. Another benefit of platelet rich plasma is its ability to form tissue over time rather than the degradation experienced by many of the compositions described above. The methods and compositions described herein may also help improve conditions other than skin condition.

In general, the method for cosmetically improving a skin condition comprises: 1) obtaining a blood sample from a subject affected by the skin condition; 2) preparing a platelet-rich plasma composition from the blood sample; 3) preparing an autologous cell composition; 4) performing a microneedling procedure on the skin area affected by said skin condition, followed by topical application of said platelet-rich composition and said autologous cell composition to the affected area. The methods are useful for treating skin conditions such as acne scars, traumatic scars, hyperpigmentation, fine lines, wrinkles, stretch marks, and hair loss.

As described further below, the platelet-rich plasma composition can serve as a carrier for an autologous cell composition. In this case, a suspension of various types of autologous cells can be produced and combined with the platelet-rich plasma prior to topical application to the skin. The extracellular matrix material that provides a scaffold for the autologous cells can also be added to the platelet rich plasma and autologous cell composition, or applied separately to the skin, or injected separately into the dermis or subcutaneous tissue. Various cell growth factors can also be added to the PRP or autologous cell composition, or applied separately to the skin surface in the form of a composition, or injected separately into the dermis or subcutaneous tissue.

When not used as a carrier, the platelet rich plasma composition and autologous cell composition can be layered in any desired order. For example, the platelet rich plasma may be applied first, followed by the autologous cell composition, or vice versa. Layering of the composition may also be repeated as desired. A tissue sealant can be applied on any layer to help keep the topically applied PRP and/or autologous cell composition within the skin. In other cases, the platelet-rich plasma, autologous cell composition, and/or extracellular matrix material are combined and injected into or under the skin, such as into the epidermis, dermis, or subcutaneous tissue, to improve skin situation. Other exemplary compositions that can be applied topically to the skin surface alone or with autologous cells and/or PRP can include cell growth factors, extracellular matrix materials (such as human amnion extracellular matrix or porcine bladder extracellular matrix), conditional media or combinations thereof. Likewise, the compositions can be layered in any desired order. These same compositions can also be injected into the dermis or subcutaneous tissue.

Detailed description of the invention

Described herein are various methods for administering platelet-rich plasma (PRP) compositions to a subject for rejuvenation of tissue (eg, skin tissue). The method will generally involve forming microporations in the surface of the skin to enhance absorption of the PRP composition therein. Autologous cells may be added to the PRP composition and then administered to the subject, or the cells may be administered as a separate composition, for example in a layer, before or after administration of the PRP composition . Layering of the compositions can improve their absorption into the skin after microneedling. In addition to PRP administration, layered administration of multiple cell compositions or administration of compositions comprising multiple cell types can also be used to improve skin appearance. For example, skin laxity, discoloration, and dull complexion can be improved using the methods and compositions described herein.

micro needling

Microperforations are typically created by microneedling devices. Any suitable microneedling device may be used. For example, devices in which needles are placed on a rotatable drum and manually rolled over the skin (dermarollers), radio frequency microneedling devices or automated microneedling devices may be used. Exemplary automated microneedling devices include, but are not limited to Microneedling device (Dermapen, Salt Lake City, UT) and Micropen ^™ microneedling device (Eclipse Aesthetics, LLC, Dallas, TX). In some variations of this method, it may be beneficial to employ an automated microneedling device. Automated microneedling devices are capable of providing consistent needle penetration depth and are convenient for use on narrow skin areas around the nose, eyes, or mouth. A lubricant is typically applied to the skin surface prior to microneedling with an automated device. Exemplary lubricants include, but are not limited to, compositions comprising one or more of: 1) hyaluronic acid; 2) adipocytes; 3) adipose-derived mesenchymal cells; 4) fibroblasts; 5) PRP; and 6) conditioned media. In one variation, the lubricant may comprise PRP. In other variations, the lubricant may include adipocytes, adipose-derived mesenchymal cells, or combinations thereof. In still other variations, the lubricant may include conditioned medium and also one or more of: 1) hyaluronic acid; 2) fibroblasts; and 3) stem cells. Application of a lubricant can help evenly distribute the pinholes in the skin.

Automated microneedling devices will typically include sterile disposable parts and reusable handles. The plurality of needles are typically secured to a disposable needle portion which is removably secured to a reusable handle. The size of the needle can vary, but is typically 32-gauge. The device can also be configured to include between six and 24 needles. In one variation, the microneedling device comprises twelve 32-gauge needles. In other variations, the microneedling device includes a needle depth adjustment mechanism that allows the needle depth to be adjusted, for example, between about 0.5 mm and 2.75 mm. Needle depth can be adjusted to suit the thickness of the skin in the affected area. For example, when performing microneedling procedures on thinner skin, such as fairer skin or the skin around the eyes, the needle depth can be set to 0.5mm. When microneedling the thicker forehead skin, the needle depth can be set between 2.5mm and 2.75mm. Other treatments or techniques for skin resurfacing and/or heating of the skin (eg, laser, radiofrequency microneedling, or ultrasound) may be employed with the methods and compositions described herein.

platelet rich plasma composition

As previously described, the methods described herein include administering a PRP composition to a subject after performing the microneedling procedure. PRP is an autologous preparation of platelets in concentrated plasma. PRP contains high concentrations of various growth factors, including platelet-derived growth factor (PDGF), transforming growth factor (TGF), vascular endothelial growth factor (VEGF), and insulin Insulin-like growth factor (IGF-1), these growth factors are secreted from the alpha granules of activated platelets. These factors are known to regulate many biological processes, including wound healing, and to promote cell migration, attachment, proliferation and differentiation, as well as extracellular matrix formation.

The PRP composition can be prepared by any suitable technique known in the art. Briefly, whole blood is first drawn from the subject. The blood is centrifuged to separate the plasma from packed red blood cells, and then centrifuged further to separate the PRP from platelet-poor plasma. The PRP can then be collected and administered to the subject as described herein.

Exemplary devices for preparing PRP include II Platelet Concentrate Isolation Kit and Plasmax ^™ Plus Plasma Concentrator Accessories (Biomet Biologics, Inc., Warsaw, Ind.), and Vortech ^™ Concentration System (Biomet Biologics, Inc., Warsaw, Ind.). System (Aesthetic Factors LLC, Bethlehem, PA) and Eclipse PRP ^™ System (Eclipse Aesthetics, Dallas, TX) are effective for in-office preparation of PRP. The platelet concentration within PRP can vary. For example, in some variations, the concentration of platelets in PRP can range from about 3 to 10 times the concentration of platelets in whole blood.

autologous cell composition

The autologous cell composition can be prepared and added to the carrier PRP composition, or applied separately before or after administration of the PRP. The autologous cell composition may comprise any suitable cell type including, but not limited to, adipocytes, adipose-derived mesenchymal cells, chondrocytes, fibroblasts, keratinocytes, stem cells, and combinations thereof. It may be beneficial to include stem cells, such as adipose stem cells, cells derived from bone marrow aspirate, or mesenchymal stem cells (eg, adipose-derived mesenchymal cells), in the composition. In practice, any undifferentiated mesenchymal cell capable of being expanded in culture may be used. For example, a composition of autologous skin fibroblasts can be prepared by expanding in culture and adding them to the PRP composition for combined administration, or expanding in culture and prior to or prior to the PRP composition. Apply thereafter.

To prepare autologous skin fibroblast compositions, cultures of skin fibroblasts were initiated from 2 x 5 mm full-thickness skin biopsy specimens. The biopsy specimens were repeatedly washed with antibiotics and antifungals before initiating culture. Thereafter, the epidermis and subcutaneous tissue containing adipocytes are removed such that the resulting culture is substantially free of non-fibroblasts, and the dermal specimen is finely dissected with scalpels or scissors. A small piece of the specimen is placed individually with forceps on the dry surface of the tissue culture flask and allowed to attach for 5 to 10 minutes, after which a small amount of medium is slowly added, being careful not to dislodge the attached tissue piece. After 24 hours of incubation, additional medium was added to the flasks. When a T-25 flask was used to start the culture, the initial amount of the medium was 1.5-2.0 ml. Establishment of cell lines from such biopsy specimens typically takes between two and three weeks, at which point cells can be removed from the initial culture vessel for expansion.

During the initial stages of culture, it is desirable that the tissue pieces remain attached to the bottom of the culture vessel. Any broken pieces should be replanted in new containers. Fibroblast growth can be stimulated by brief exposure of the tissue culture to EDTA-trypsin according to techniques well known to those skilled in the art. This exposure to trypsin is too brief to detach the fibroblasts from the walls of the culture vessel to which they are attached. A sample of fibroblasts can be removed for frozen storage immediately after the culture is established and approaches confluence. Cryostorage of earlier rather than later passage fibroblasts is preferred because the number of passages in cell culture of normal human fibroblasts is limited.

Fibroblasts can be frozen in any freezing medium suitable for preserving fibroblasts. A medium consisting of 70% growth medium, 20% (v/v) fetal bovine serum and 10% (v/v) dimethylsulfoxide (DMSO) can be used with good effect. Thawed cells can be used to initiate subculture to obtain a suspension for the same subject without the inconvenience of obtaining a second specimen.

Any tissue culture technique suitable for the proliferation of dermal fibroblasts from a biopsy specimen can be used to expand the cells. Available in R.I.Freshney, Ed., ANIMAL CELL CULTURE: A PRACTICAL APPROACH (IRLPress, Oxford England, 1986) and R.I.Freshney, Ed., CULTURE OF ANIMAL CELLS: A MANUALOF BASIC TECHNIQUES, Alan R. Liss & Co., New York, 1987 ) to find techniques well known to those skilled in the art.

The medium can be any medium suitable for the growth of primary fibroblast cultures. In most cases, the medium was supplemented with serum in an amount of 0.5%-20% (v/v) to promote the growth of fibroblasts. Higher concentrations of serum promote faster growth of fibroblasts. In one variation, the serum is fetal calf serum, which is added to a final concentration of 10% of the medium. For example, the medium may comprise high glucose DMEM ("complete medium") supplemented with 2 mM glutamine, 110 mg/L sodium pyruvate, 10% (v/v) fetal calf serum, and antibiotics.

Cells can be passaged to new flasks by trypsinization. Individual flasks can be split 1:3 for expansion. A triple bottom T-150 culture flask with a total culture area of 450 ^cm2 is suitable for use. The triple bottom T-150 is capable of seeding approximately ⁶ x 106 cells and has the capacity to produce approximately 1.8 x ¹⁰⁷ cells. When the capacity of the flask is reached (which typically requires 5-7 days of culture), the growth medium is replaced with serum-free complete medium; thereafter the cells are cultured in protein-free medium, i.e. maintained at approximately 30°C- Between about 40°C for at least 6 hours, preferably greater than 12 hours, most preferably 16-18 hours (preferably 37°C). Culturing of the cells in serum-free medium essentially removes from the cells proteins derived from fetal bovine serum that, if present, would be immunogenic and cause an allergic reaction in the subject.

After expansion, cells are removed from tissue culture flasks by trypsin/EDTA; washed extensively by centrifugation and resuspension; and suspended in a carrier material such as PRP or isotonic saline. The cells will not be suspended or cultured in a fibrin clot. Six triple bottom T-150 flasks grown to capacity yielded approximately ¹⁰⁸ cells, which was sufficient to make up approximately 1.0 ml of suspension.

In some variations, cells can be shipped at 4°C as long as they are used within 18 hours of making the suspension. Cells can be suspended in an equal volume of complete medium, but without the phenol red pH indicator, and fetal calf serum replaced with the subject's serum for this transport (transport medium). Cells can be aspirated and injected into the transport medium. The volume of saline or transport medium in which the cells are suspended is not critical and may depend on factors such as the number of fibroblasts the physician desires to use, the size and number of defects to be treated, and the subject's desire to obtain a therapeutic outcome. urgency.

Alternatively, instead of using the flask-based cell expansion system described above, an automated closed cell expansion system (e.g. The Cell Expansion System (Terumo BCT, Inc., Lakewood, CO)) produces autologous skin fibroblast compositions as well as other autologous cell compositions (eg, adipose-derived mesenchymal cell compositions). An exemplary automated closed cell expansion system may employ a hollow fiber cell growth bioreactor. These three-dimensional bioreactors can contain more than 10,000 individual hollow fibers approximately 200 microns long, the inner surfaces of which can produce a total growth surface area of more than two square meters (a typical large tissue culture flask can have a diameter between about 150 and about 175 square centimeters). growth area between them). It will be appreciated that the total growth surface area can be adjusted by varying the number and/or length of the hollow fiber bioreactors employed. The large surface area of automated closed cell expansion systems is generally designed to maximize the expansion of adherent cells (eg, bone marrow cells, adipocytes, mesenchymal stem cells, amniocytes, epithelial cells, etc.) in the smallest volume. Furthermore, the defined and stable geometry of hollow fiber bioreactors allows for optimal control and management of the cell culture environment. The closed environment of the bioreactor typically remains intact throughout the culture process, eliminating the open handling and fieldwork associated with traditional, flask-based tissue culture. Thus, such automated closed cell expansion systems generally reduce the risk of operator error and contamination.

In other variations, a hybrid approach may be taken. For example, in a medium containing a small amount of fetal bovine serum (e.g., 2% to 3% fetal bovine serum) (such as FGM ^™ -2 Fibroblast Growth Medium (Lonza Group Ltd., Basel , Switzerland)) to establish primary fibroblast cultures with one or two passages, and then use an automated closed system (such as Cell Expansion System) is expanded using serum-free media such as serum-free, chemically defined media such as FGM-CD ^™ (Lonza Group Ltd., Basel, Switzerland)).

extracellular matrix material

In some variations of the methods described herein, the PRP composition and autologous cell composition can be supplemented with a biocompatible extracellular matrix (ECM) material. The ECM material can act as a scaffold to hold or support autologous cells at the site of administration. For example, the ECM material can maintain or support fibroblasts cultured and expanded as described above. In addition, the ECM material can promote migration of endogenous cells into the area of application. The ECM material can be injected or topically applied to the area affected by the skin condition, followed by the application of PRP and autologous cells. Alternatively, the PRP composition or autologous cell composition may be combined with the ECM material and then administered, for example by topical application or by injection.

ECM materials may comprise natural, synthetic or semi-synthetic materials as long as they are biocompatible. Exemplary ECM materials include human amniotic extracellular matrix and porcine bladder matrix. Other ECM materials may include polymers. Suitable polymers may include, but are not limited to, gelatin, hyaluronic acid, chitosan, polyglycolic acid, polylactic acid, polypropylene fumarate, polyethylene glycol, and copolymers and combinations thereof.

apply

The methods described herein can be used to cosmetically improve the condition of the skin, typically with a microneedling step prior to application of the PRP and autologous cell composition. However, PRP with or without autologous cell composition can also be used as a lubricant for microneedling devices. As previously mentioned, microneedling of the affected area improves absorption of the composition into the area and enhances tissue regeneration. In general, a method for cosmetically improving a skin condition comprises the steps of: 1) obtaining a blood sample from a subject affected by the skin condition; 2) preparing a platelet-rich plasma composition from said blood sample; 3) preparing an autologous cell composition; and 4) performing a microneedling procedure on an area of skin affected by said skin condition, followed by topically applying said platelet-rich composition and said autologous cell composition to the affected area. In some variations, the autologous cell composition comprises fibroblasts. In other variations, the autologous cell composition comprises adipocytes. In yet other variations, the autologous cell composition comprises stem cells, such as adipose-derived mesenchymal cells. In some cases, it may be useful to include fibroblasts and adipose-derived mesenchymal cells in the autologous cell composition.

Microneedling and application of the PRP and autologous cell composition can be repeated 4 to 6 times every 4 to 6 weeks, however, other microneedling and application regimens can be performed depending on the skin condition being treated and the severity of the condition. Repeated microneedling and PRP and autologous cell administration can often stimulate previously administered cells. In some cases, it may be beneficial to apply heat via ultrasound, radio frequency or laser devices where PRP and cells have been previously applied to the tissue. For example, heat can be applied to previously administered cells (in a different clinic) at a later date. Skin conditions that may be improved by such methods include, but are not limited to, acne scars, traumatic scars, hyperpigmentation, fine lines, wrinkles, stretch marks, and hair loss.

When a PRP composition is used as a carrier, cultured autologous cells can be suspended in PRP and then applied topically to a desired area, such as an area affected by a skin condition. In some variations, it may be beneficial to topically apply the PRP composition in which the cultured fibroblasts have been suspended. In another variation, it may be beneficial to topically apply a PRP composition in which cultured adipocytes have been suspended. Alternatively, it may be beneficial to topically apply a PRP composition in which cultured adipose-derived mesenchymal cells have been suspended. Extracellular matrix material that provides a scaffold for autologous cells may also be added to the PRP composition or autologous cell composition, or applied separately to the affected area.

When not used as a carrier, the PRP composition and autologous cell composition can be layered in any desired order. For example, the platelet rich plasma may be applied first, followed by the autologous cell composition, or vice versa. Layering of the composition may also be repeated as desired. In some variations, a layer of adipocytes or adipose-derived mesenchymal cells is applied to the skin prior to microneedling. In other variations, the adipocytes or adipose-derived mesenchymal cells are combined with fibroblasts and then layered onto the skin prior to microneedling. As noted above, enhanced tissue regeneration and improved skin appearance can be obtained by administering PRP and one or more cellular compositions.

Tissue sealants may be applied on any layer to help retain topically applied PRP and/or autologous cell compositions within the skin, and thus improve their absorption. For example, locally applied on one or more layers Fibrin sealant (Baxter International Inc., Deerfield, IL). In other cases, the PRP, autologous cell composition, and/or extracellular matrix material are combined and injected into or under the skin, such as into the epidermis, dermis, or subcutaneous tissue, to improve skin situation.

The PRP compositions, autologous cell compositions, tissue sealants, cell growth factors and extracellular matrix materials can be administered to any area of the body where cosmetic improvement is desired. For example, the compositions and materials may be applied to areas of the face, neck, hands, and the like. Application will generally include topical application by spreading the composition onto the skin, but may also include spray application.

In some instances, the compositions described herein are used as fillers and injected into the dermis or subcutaneous tissue. The volume of the composition can help improve cosmetic appearance or treat skin conditions. Injection of one or more compositions may be performed in addition to microneedling and/or layering of PRP and/or layering of an autologous cell composition. Exemplary compositions for injection may include PRP, autologous cell compositions, conditioned medium, ECM material comprising, for example, human amniotic membrane or porcine bladder, cell growth factors, or combinations thereof. The autologous cell composition may comprise any one or more of the cell types described herein, such as fibroblasts, adipocytes, and mesenchymal cells. In some variations, injections of PRP and fibroblasts, PRP and adipocytes, or PRP and adipose-derived mesenchymal cells may be useful. Other variations of the method may include injection of conditioned medium and fibroblasts, conditioned medium and adipocytes, or conditioned medium and adipose-derived mesenchymal cells.

Injections may be beneficial when treating wrinkles or deep acne scars. In a specific variation where the skin condition is superficial fine lines, the affected area is prepped with alcohol and stretched to give a taut surface. A syringe was then filled with fibroblasts suspended in the PRP composition and fitted with a 30-gauge needle for injection. Insert the needle into the skin site as shallowly as possible; the orientation of the bevel is not critical. Intradermal injections are given by gentle pressure until slight blanching is seen. Multiple series of injections are then performed. A similar procedure can be used for rejuvenation of hair.

In yet other variations, methods for improving cosmetic appearance or improving skin condition involve a multimodal approach. The method herein may take into account the subject's needs for tissue volume, deep and superficial tissue lifting and toning, dermal restoration and/or epidermal restoration. When tissue volume is desired, the method can include the use of injectable fillers as described herein, cell therapy (e.g., layering with one or more autologous cell compositions described herein), and/or administration of cellular growth factors . When it is desired to improve skin laxity, skin tone and/or dull complexion, the method may include any one or more of: microneedling with an automated device as described herein, cell therapy (e.g., with a layered with one or more autologous cell compositions), application of cell growth factors, radiofrequency microneedling, deep ultrasonic heating and fractionated laser. Similarly, the appearance of fine lines and nasolabial folds can be improved by injectable fillers as described herein, microneedling with a robotic device as described herein, cell therapy (e.g., with one or more of the autologous cell composition), administration of cell growth factors, radiofrequency microneedling and/or deep ultrasonic heating are improved. Methods for improving stretch marks can include cell therapy (e.g., layering with one or more autologous cell compositions as described herein), microneedling with a robotic device as described herein, administration of cellular growth factors and/or radiofrequency microneedling. In some variations, hyperpigmentation can be improved using an automated microneedling device and administration of cellular growth factors as described herein. Where improvement of acne scarring is desired, the method may include any one or more of: fat grafting using their mesenchymal stem cells, subcutaneous excision, cell therapy (e.g., using one or more of the autologous cells described herein composition), microneedling with a robotic device as described herein, application of cellular growth factors, radiofrequency microneedling, and laser resurfacing. Where hair loss is to be improved, the method may include microneedling with a robotic device as described herein, cell therapy (e.g., layering with one or more autologous cell compositions as described herein), and administering cell growth factor.

Claims (26)

1. A method for cosmetically improving skin condition comprising: obtaining a blood sample from a subject affected by the skin condition; preparing a platelet-rich plasma composition from said blood sample; preparing an autologous cell composition; Microneedling is performed on the area of skin affected by the skin condition, followed by topically applying the platelet-rich composition and the autologous cell composition to the affected area. 2. The method of claim 1, wherein the microneedling operation is performed by an automated microneedle device comprising a plurality of needles secured to a disposable needle portion and detachably secured to The reusable handle of the disposable needle. 3. The method of claim 2, wherein the automated microneedle device further comprises a needle depth adjustment mechanism. 4. The method of claim 3, wherein performing the microneedling manipulation comprises adjusting the depth of the plurality of needles using the depth adjustment mechanism. 5. The method of claim 4, wherein the depth of the plurality of needles is adjusted to be between 0.5mm and 2.75mm. 6. The method of claim 1, wherein the platelet rich plasma composition and autologous cell composition are mixed together and applied topically to the affected area. 7. The method of claim 1, wherein the platelet-rich plasma composition is applied to the affected area, followed by administration of the autologous cell composition. 8. The method of claim 7, further comprising repeated topical administration of the platelet-rich plasma composition. 9. The method of claim 1, wherein the autologous cell composition is applied to the affected area, followed by topical administration of the platelet-rich plasma composition. 10. The method of claim 1, further comprising topically applying a tissue sealant on the platelet-rich plasma composition or the autologous cell composition. 11. The method of claim 1, wherein the autologous cell composition comprises adipocytes, adipose-derived mesenchymal cells, chondrocytes, fibroblasts, keratinocytes, stem cells, or combinations thereof. 12. The method of claim 1, wherein the autologous cell composition comprises fibroblasts. 13. The method of claim 1, wherein the autologous cell composition comprises adipocytes. 14. The method of claim 1, wherein the autologous cell composition comprises adipose-derived mesenchymal cells. 15. The method of claim 1, wherein the autologous cell composition comprises fibroblasts, and adipocytes or adipose-derived mesenchymal cells. 16. The method of claim 1, further comprising applying a biocompatible extracellular matrix material to the affected area. 17. The method of claim 16, wherein the biocompatible extracellular matrix material comprises human amniotic tissue matrix. 18. The method of claim 16, wherein the biocompatible extracellular matrix material comprises porcine bladder matrix. 19. The method of claim 1, further comprising applying a lubricant to the skin area prior to the microneedling procedure. 20. The method of claim 19, wherein the lubricant comprises platelet-rich plasma, adipocytes, adipose-derived mesenchymal cells, or combinations thereof. 21. The method of claim 1, wherein the skin condition is selected from the group comprising acne scars, traumatic scars, hyperpigmentation, fine lines, wrinkles, stretch marks, and hair growth. 22. The method of claim 1, further comprising injecting an autologous cell composition into the affected area. 23. The method of claim 22, wherein the autologous cell composition comprises adipocytes, adipose-derived mesenchymal cells, chondrocytes, fibroblasts, keratinocytes, stem cells, or combinations thereof. 24. The method of claim 22, wherein the autologous cell composition comprises fibroblasts. 25. The method of claim 22, wherein the autologous cell composition comprises adipocytes. 26. The method of claim 22, wherein the autologous cell composition comprises adipose-derived mesenchymal cells.